Recombinant TIM3 antibody (Extracellular Domain)

Catalog No. ABIN7072498

This Rat Monoclonal antibody specifically detects TIM3 in FACS, IHC, IF and BP. It exhibits reactivity toward Mouse.

Quick Overview for Recombinant TIM3 antibody (Extracellular Domain) (ABIN7072498)

Target: TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))

Antibody Type: Recombinant Antibody

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This TIM3 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunofluorescence (IF), Blocking Peptide (BP)

Clone: 2C12

Product Details anti-TIM3 Antibody

Binding Specificity: Extracellular Domain

Purpose: Anti-Tim-3 [2C12], Rat IgG1, kappa

Specificity:

This antibody is specific for murine TIM-3, a Th1-specific cell surface protein. TIM-3 is a type I transmembrane protein and contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. This antibody binds to the BALB/c allele of TIM-3 while reactivity to the C57Bl/6 allele is significantly weaker.

Application Notes original Clone: This antibody was used in FACS, immunohistochemistry, immunofluorescence and a murine experimental autoimmune encephalomyelitis model to study the effects of TIM-3 triggering in dendritic cells (Anderson et al., 2007, PMID: 18006747). Furthermore, this antibody has been used in multiple FACS analyses for diverse immuno-oncological applications, such as to delineate how TIM-3 signaling on cells of the innate immune system critically influences regulation of the adaptive immune response (Frisancho-Kiss et al., 2006), to demonstrate the reversal of T cell exhaustion and restoration of anti-tumor immunity upon co-targeting Tim-3 and PD-1 pathways (Sakuishi et al., 2010, PMID: 20819927), and to examine the therapeutic potential of dendritic cell based vaccines against malignant glioma (Dey et al., 2015). This antibody has also been used in immunohistochemistry to aid the elucidation of the effects of Th2 immune deviation on corneal allograft survival and possible mechanisms of graft rejection (Beauregard et al., 2005). In addition, employing this anti-TIM-3 antibody as part of the combination immuntherapy (anti-TIM3 + anti-PD-1 +/- anti-CTLA-4) has been shown to be effective against experimental and carcinogen-induced tumors in mice (Sakuishi et al., 2010, PMID: 20819927) (Ngiow et al., 2011, PMID: 21430066).

Purification: Protein A affinity purified

Immunogen: This antibody was raised by immunising rats with TIM-3:Ig fusion protein emulsified in complete Freund's adjuvant.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

OriginalSpeciesName: Rat

OriginalFormat: IgG1

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for TIM3

Target: TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))

Alternative Name: Tim-3

Target Type: Virus

Background: CD366, HAVcr-2, HAVCR2, Hepatitis A virus cellular receptor 2 homolog, T-cell immunoglobulin and mucin domain containing 3, T-cell immunoglobulin and mucin domain-containing protein 3, T-cell immunoglobulin mucin receptor 3, T-cell membrane protein 3, TIM-3, TIMD-3, TIM3, 8B.2C12

UniProt: Q8VIM0

Pathways: Regulation of Lipid Metabolism by PPARalpha, Cancer Immune Checkpoints